| Literature DB >> 20604924 |
Linn Gjersing1, Helge Waal, John R M Caplehorn, Michael Gossop, Thomas Clausen.
Abstract
BACKGROUND: In opioid maintenance treatment (OMT) there are documented treatment differences both between countries and between OMT programmes. Some of these differences have been associated with staff attitudes. The aim of this study was to 1) assess if there were differences in staff attitudes within a national OMT programme, and 2) investigate the associations of staff attitudes with treatment organisation, clinical practices and outcomes.Entities:
Mesh:
Year: 2010 PMID: 20604924 PMCID: PMC2911430 DOI: 10.1186/1472-6963-10-194
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
The 13-item scale measuring attitudes towards opioid maintenance treatment*
| 1 | OMT patients who ignore repeated warnings to stop using heroin should be gradually withdrawn off methadone |
|---|---|
| 2 | OMT patients who continue to abuse non-opioid drugs (e.g. benzodiazepines) should have their dose of OMT medication reduced. |
| 3 | If repeated warnings of non-prescriptive use of benzodiazepines are ignored, the patient should be discharged from the OMT programme |
| 4 | If repeated warnings of use of Cannabis are ignored, the patient should be discharged from treatment (OMT) |
| 5 | The GP should waive the right to prescribe class A and B drugs other than the OMT medication to OMT patients |
| 6 | OMT patients who continue to take drugs and function poorly should be discharged from the OMT programme |
| 7 | It is unethical to discharge patients from the OMT programme due to continuing drug use and poor functioning** |
| 8 | OMT services should be expanded so all heroin addicts who want OMT can receive it** |
| 9 | It is unethical to deny heroin addicts OMT** |
| 10 | OMT's main aim is to reduce harmful effects of opioids and IV drug use (syringes)** |
| 11 | GPs should be able to initiate OMT on their own initiative** |
| 12 | Too many OMT-patients are discharged from the OMT programme** |
| 13 | Young opioid dependents (< 20) should not be offered OMT |
*Participants were asked to rate their responses to each item on a five-point Likert scale from strongly disagree = 1 to strongly agree = 5.
** Reversed scores
Treatment characteristics and practices for OMT centres when divided into attitudinal groups
| Characteristics for each group | "Harm reduction-oriented" centres | "Intermediate" centres | "Rehabilitation-oriented" centres |
|---|---|---|---|
| Total number of patients per group | 1980 | 1513 | 1049 |
| Patient/staff ratio | 64 | 50 | 34 |
| Methadone dose (mg)* | 111 mg | 111 mg | 106 mg |
| Buprenorphine dose (mg)* | 18 mg | 17 mg | 20 mg |
| Number of supervised dispensing per patient per week* | 4.1 | 3.9 | 3.7 |
| Number of patients urine drug screened at least once a week *† | 62% | 73% | 74% |
| Interdisciplinary meeting previous 4 weeks*† | 46% | 49% | 59% |
*Median
† Number of patients in brackets
†† Not all items in each patient questionnaire were completed, thus the total number of respondents for each item varied from the total number of patients at each centre.
Treatment outcomes for OMT centres when divided into attitudinal groups
| Treatment outcomes for each group | "Harm reduction-oriented" centres | "Intermediate" centres | "Rehabilitation-oriented" centres | Prevalence difference* (95% CI) | p-value** |
|---|---|---|---|---|---|
| Opioids use previous 4 week | 18% | 15% | 14% | 4% (1%; 7%) | 0.022 |
| Central stimulant drug use previous 4 week | 19% | 19% | 16% | 3% (-1%; 6%) | 0.102 |
| Benzodiazepine use previous 4 weeks | 55% | 50% | 32% | 23% (18%; 29%) | < 0.001 |
| Cannabis use previous 4 weeks | 46% | 41% | 21% | 25% (20%; 29%) | < 0.001 |
| Unemployed in treatment | 83% | 77% | 66% | 17% (10%; 23%) | < 0.001 |
| Social security benefits as main income | 24% | 15% | 12% | 12% (9%; 15%) | < 0.001 |
| Long-term living arrangements for patients in treatment | 71% | 82% | 86% | -15% (-21%; -8%) | < 0.001 |
| Treatment termination rate | 11% | 9%† | 15% | - 4% (-8%; - 2%) | < 0.001 |
Total number of patients (n) per item in brackets
*Prevalence difference in percent. It was calculated by subtracting the prevalence of "harm reduction-oriented" centres from the prevalence of the "rehabilitation-oriented" centres.
**P-values estimated for prevalence difference
† Prevalence difference ("rehabilitation-oriented" vs. "intermediate" centres) 5% (4%; 9%), p-value < 0.001)
††Not all items in each patient questionnaire were completed, thus the total number of respondents for each item varied from the total number of patients at each centre.